These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16322343)

  • 1. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
    Symmans WF; Fiterman DJ; Anderson SK; Ayers M; Rouzier R; Dunmire V; Stec J; Valero V; Sneige N; Albarracin C; Wu Y; Ross JS; Wagner P; Theriault RL; Arun B; Kuerer H; Hess KR; Zhang W; Hortobagyi GN; Pusztai L
    Endocr Relat Cancer; 2005 Dec; 12(4):1059-69. PubMed ID: 16322343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting features of breast cancer with gene expression patterns.
    Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
    Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
    Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
    Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
    Biswas DK; Iglehart JD
    J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.